VIA
SNDX icon

Virtus Investment Advisers’s Syndax Pharmaceuticals SNDX Stock Holding History

Virtus Investment Advisers’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Buy
63,720
+22,275
+54% +$463K 0.32% 136
2026
Q1 		$968K Buy
41,445
+7,896
+24% +$172K 0.27% 143
2025
Q4 		$705K Buy
33,549
+22,885
+215% +$399K 0.19% 161
2025
Q3 		$164K Buy
10,664
+1,851
+21% +$24.2K 0.05% 363
2025
Q2 		$82.5K Sell
8,813
-3,379
-28% -$37.2K 0.03% 412
2025
Q1 		$150K Buy
+12,192
New +$172K 0.04% 333

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Virtus Investment Advisers's SNDX Position: Q2 2026 in Review

Virtus Investment Advisers increased its Syndax Pharmaceuticals (SNDX) stake by 54% in Q2 2026, buying an estimated $463K and bringing the position to 63,720 shares worth $1.39M. The position accounts for 0.32% of the portfolio, ranked #136.

Virtus Investment Advisers first reported a position in SNDX in Q1 2025 and has held it in 6 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Virtus Investment Advisers held 63,720 shares of Syndax Pharmaceuticals worth $1.39M as of Q2 2026.
  • Virtus Investment Advisers bought 22,275 Syndax Pharmaceuticals shares in Q2 2026, an estimated $463K.
  • Syndax Pharmaceuticals made up 0.32% of Virtus Investment Advisers's portfolio in Q2 2026, its #136 holding.
  • Virtus Investment Advisers first reported a position in Syndax Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.